Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
European Journal of Cancer2017Vol. 81, pp. 116–129
Citations Over TimeTop 1% of 2017 papers
Leisha A. Emens, Paolo A. Ascierto, Phillip K. Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco M. Marincola
Related Papers
- → Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators(2020)80 cited
- → A Pooled Analysis of Nivolumab for the Treatment of Advanced Non-Small-Cell Lung Cancer and the Role of PD-L1 as a Predictive Biomarker(2016)33 cited
- → <p>Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date</p>(2019)11 cited
- → P1.23-02 Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC(2023)
- → EP13.05-01 Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide(2023)